Sumitomo Pharmaceuticals Company Limited

Sumitomo Chemical Company, Limited

Koken Company, Limited

Yamanouchi Pharmaceutical Company Ltd.

Shigeji Sato

Keiji Fujioka

Yoshihiro Takada

Yoshiya Yamahira

Yoshio Sasaki

Nobuhiko Tamura

Teruo Miyata

Masayasu Furuse

Yoshiko Okuzawa

Hiromi Naito

Tetsuo Noguchi

Seiko Miura

Tadao Maeda

Takeshi Noguchi

Reimei Ishikawa

Miho Maeda

Terutsugu Tsuji

Porous solid formulations containing proteinaceous physiologically

The present invention relates to a sustained-release injection, which comprises a suspension of a powder comprising an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, polysaccharides and synthetic high molecular compounds, preferably collagen, atelocollagen, gelatin, and a mixture thereof) in a viscous solvent for injection (e.g. vegetable oils, polyethylene glycol, propylene glycol, silicone oil, and medium-chain fatty acid triglycerides). The sustained-release injection can release the active ingredient at an effective level for a long period of time when injected.

Sustained-release injection

A controlled release formulation which comprises a compound selected from the group consisting of organic acidic compounds and acid anhydrides or esters capable of generating one of the organic acidic compounds through hydrolysis together with an active ingredient and collagen as a carrier, said formulation being capable of exhibiting a predetermined release profile of the active ingredient. A process for producing said formulation is also provided.

Controlled release formulation

A method for drying a wetted molded product of pasty high viscous composition which comprises subjecting the molded product to a dehydration process while wholly or partially contacting the product with an open-cell foamed hydrophobic porous membrane.

Method for drying wetted molded product

A sustained-release preparation of indomethacin or interferon comprising the active ingredient in admixture with a pharmaceutically acceptable biodegradable carrier, particularly a carrier selected from collagen, gelatin, and a mixture thereof. Said preparation is particularly suitable for parenteral administration and can release the active ingredient in an effective amount for a long period of time.

Sustained-release preparation

A solid sustained-release preparation in the form of a needle-like or bar-like shape, which consists essentially of an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, preferably collagen, gelatin, and a mixture thereof). The sustained release preparation can be administered to the body or implanted into the body by injection or an injection-like method and can release the active ingredient at an effective level for a long period of time when administered.

Long-term sustained-release preparation

The invention relates to sustained pulsewise release pharmaceutical preparation which comprices drug-containing polymeric material layers (layers A) and polymeric material layers containing the drug in question only in a slight amount or free of the drug (layers B) disposed alternatingly, with the whole surface extending in the direction perpendicular to the layer plane being coated with a polymeric material which is insoluble in water or scarcely soluble in water (polymeric material C). This pharmaceutical preparation of this invention is designed so that active ingredients which should desirably be released pulsewise can be released therefrom in a pulse-like and clinically significant manner and thereby the pharmacological effects of said active ingredients can be maintained for a prolonged period of time.

Sustained pulsewise release pharmaceutical preparation

A sustained release composition applicable for human beings and mammals which comprises (a) a silicone elastomer and (b) a pharmaceutical substance optionally with (c) albumin. When the pharmaceutical substance is of high molecular weight, and can exert its pharmaceutical effect in a trace amount, its continuous release over a long period is attained by application of this invention.

Sustained release composition for pharmaceutical substances comprising a

Growth hormone releasing factor (GRF) preparation which is excellent in stablity by having human serum albumin or glycine incorporated therein, with or without buffer. An amount of human serum albumin or glycine contained is usually 100 .mu.g to 30 mg per 100 .mu.g GRF. The preparation may be in the solid or solution form, preferably in the lyophilized form. An amount of buffer, if added, is preferably enough so that pH of the preparation is kept at 2-7. More preference is that the preparation is kept in nitrogen gas atmosphere. The lyophilized preparation is readily usable for, for example, injection.

Stable growth hormone releasing factor preparation

A device for administering solid or semisolid preparations under the skin, which comprises a solid needle member with an acute tip end, and a cylindrical member slidably mounted on the needle member. The solid needle member having a recess at its front part to form a preparation chamber between the needle member and cylindrical member, and the chamber being opened or closed by moving the cylindrical member in the direction parallel to the axis of the needle member. The device may comprises a cylindrical member with a capsule chamber, a hollow needle member removable mounted on the front end of the cylindrical member, and a plunger slidably arranged in the capsule chamber of the cylindrical member, all of which have a common axis so that the plunger enters into the hollow needle member through the capsule chamber.

Solid preparation administering instrument

An antimicrobial preparation of D-7-[.alpha.-(4-hydrooxy-6-methylnicotinamido)-4-hydroxyphenylacetamido]-3 -(1-methyltetrazol-5-yl)thiomethyl-.DELTA..sup.3 -cephem-4-sodium carboxylate (hereinafter referred to as 'Compound A' of enhanced stability is disclosed, which comprises a microbially effective amount of Compund A and a stabilizer selected from the class consisting of benzoic acid, sodium benzoate and nicotinamide.

Antimicrobial preparation

A sustained-release preparation of indomethacin or interferon comprising the active ingredient in admixture with a pharmaceutically acceptable biodegradable carrier, particularly a carrier selected from collagen, gelatin, and a mixture thereof. The preparation is particularly suitable for parenteral administration and can release the active ingredient in an effective amount for a long period of time.

A method for preparing a sustained release formulation utilizing collagen and/or gelatin as a carrier, which comprises the steps:

Method for producing sustained release formulation

A composition comprising as the pharmaceutically active ingredient bencyclane fumarate and cyclodextrin. As compared with prior bencyclane fumarate preparations, this composition can greatly decrease the adverse effects of bencyclane fumarate and, in addition, offers considerable advantages from the viewpoints of method of use and method of production of preparation.

Pharmaceutical composition comprising bencyclane fumarate and

A method for preparing a stable urokinase injection by the liophilization of urokinase which comprises liophilizing an aqueous solution containing urokinase, human serum albumin and one or more amino acid compounds selected from polar amino acids and salt thereof. The urokinase injection obtained according to this method is excellent in the storing stability as compared with conventional urokinase preparations for injection.

Growing community of inventors

Ibaraki, Japan

Shigeji Sato